CN100415745C - 作为可诱导的no合成酶抑制剂的咪唑并吡啶衍生物 - Google Patents

作为可诱导的no合成酶抑制剂的咪唑并吡啶衍生物 Download PDF

Info

Publication number
CN100415745C
CN100415745C CNB2004800275920A CN200480027592A CN100415745C CN 100415745 C CN100415745 C CN 100415745C CN B2004800275920 A CNB2004800275920 A CN B2004800275920A CN 200480027592 A CN200480027592 A CN 200480027592A CN 100415745 C CN100415745 C CN 100415745C
Authority
CN
China
Prior art keywords
compound
hydrogen
methyl
formula
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2004800275920A
Other languages
English (en)
Chinese (zh)
Other versions
CN1856491A (zh
Inventor
T·福赫斯
T·马丁
R·贝尔
A·斯特拉布
M·埃尔策
M·勒纳
W·-R·乌尔里希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Altana Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma AG filed Critical Altana Pharma AG
Publication of CN1856491A publication Critical patent/CN1856491A/zh
Application granted granted Critical
Publication of CN100415745C publication Critical patent/CN100415745C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
CNB2004800275920A 2003-10-01 2004-09-30 作为可诱导的no合成酶抑制剂的咪唑并吡啶衍生物 Expired - Fee Related CN100415745C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03022053.7 2003-10-01
EP03022053 2003-10-01

Publications (2)

Publication Number Publication Date
CN1856491A CN1856491A (zh) 2006-11-01
CN100415745C true CN100415745C (zh) 2008-09-03

Family

ID=34384571

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004800275920A Expired - Fee Related CN100415745C (zh) 2003-10-01 2004-09-30 作为可诱导的no合成酶抑制剂的咪唑并吡啶衍生物

Country Status (19)

Country Link
US (2) US7468377B2 (cg-RX-API-DMAC7.html)
EP (1) EP1675854B1 (cg-RX-API-DMAC7.html)
JP (1) JP2007507467A (cg-RX-API-DMAC7.html)
KR (1) KR20060092220A (cg-RX-API-DMAC7.html)
CN (1) CN100415745C (cg-RX-API-DMAC7.html)
AT (1) ATE399169T1 (cg-RX-API-DMAC7.html)
AU (1) AU2004276015A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0414972A (cg-RX-API-DMAC7.html)
CA (1) CA2540083A1 (cg-RX-API-DMAC7.html)
DE (1) DE602004014630D1 (cg-RX-API-DMAC7.html)
EA (1) EA010261B1 (cg-RX-API-DMAC7.html)
ES (1) ES2309567T3 (cg-RX-API-DMAC7.html)
IL (1) IL173895A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06003349A (cg-RX-API-DMAC7.html)
NO (1) NO20061344L (cg-RX-API-DMAC7.html)
NZ (1) NZ546437A (cg-RX-API-DMAC7.html)
RS (1) RS20060196A (cg-RX-API-DMAC7.html)
WO (1) WO2005030771A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200601642B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06003351A (es) * 2003-10-01 2006-06-08 Altana Pharma Ag Derivados de imidazopiridina como inhibidores de no-sintasa inducible.
KR20060092220A (ko) * 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타아제 저해제로서의 이미다조피리딘 유도체
KR20060092221A (ko) 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타제 억제제로서의이미다조（4,5-ｂ）피리딘 유도체
EP1670798A1 (en) 2003-10-01 2006-06-21 Altana Pharma AG Aminopyridine-derivatives as inductible no-synthase inhibitors
AR057525A1 (es) * 2005-10-03 2007-12-05 Astrazeneca Ab Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion
AR055669A1 (es) * 2005-10-03 2007-08-29 Astrazeneca Ab Derivados de 3h - imidazo[4, 5 -b]piridina como inhibidores selectivos de gsk3, metodos e internediarios para su preparacion, composiciones farmaceuticas que los contienen y su uso para la elaboracion de un medicamento para el tratamiento de enfermedades neurodegenerativas y mentales.
ES2573412T3 (es) * 2010-09-10 2016-06-07 Shionogi & Co., Ltd. Derivado de imidazol de heteroanillo fusionado que tiene efecto de AMPK (activacion de proteina cinasa activada por monofosfato de adenosina)
GB201512635D0 (en) 2015-07-17 2015-08-26 Ucl Business Plc Uses of therapeutic compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2504252A1 (de) * 1974-02-18 1975-08-21 Haessle Ab Heterocyclische verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel
EP0125756A2 (en) * 1983-03-22 1984-11-21 Fujisawa Pharmaceutical Co., Ltd. Fused imidazole compounds, processes for the preparation thereof and pharmaceutical compositions containing them
WO2000049015A1 (en) * 1999-02-17 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds and their pharmaceutical use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4045564A (en) * 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
SE512835C2 (sv) 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
ATE384722T1 (de) * 2002-03-27 2008-02-15 Nycomed Gmbh Alkoxypyridinderivate
AU2003280578A1 (en) * 2002-10-30 2004-05-25 Ajinomoto Co., Inc. Heterocyclic compounds
MXPA06003351A (es) * 2003-10-01 2006-06-08 Altana Pharma Ag Derivados de imidazopiridina como inhibidores de no-sintasa inducible.
KR20060092220A (ko) * 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타아제 저해제로서의 이미다조피리딘 유도체
KR20060092221A (ko) 2003-10-01 2006-08-22 알타나 파마 아게 유도성 ｎｏ-신타제 억제제로서의이미다조（4,5-ｂ）피리딘 유도체
BRPI0414873A (pt) 2003-10-01 2006-12-12 Altana Pharma Ag derivados de imidazopiridina como inibidores de no-sintase induzìveis
EP1670798A1 (en) 2003-10-01 2006-06-21 Altana Pharma AG Aminopyridine-derivatives as inductible no-synthase inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2504252A1 (de) * 1974-02-18 1975-08-21 Haessle Ab Heterocyclische verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel
EP0125756A2 (en) * 1983-03-22 1984-11-21 Fujisawa Pharmaceutical Co., Ltd. Fused imidazole compounds, processes for the preparation thereof and pharmaceutical compositions containing them
WO2000049015A1 (en) * 1999-02-17 2000-08-24 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds and their pharmaceutical use

Also Published As

Publication number Publication date
ZA200601642B (en) 2007-05-30
US7468377B2 (en) 2008-12-23
CN1856491A (zh) 2006-11-01
NZ546437A (en) 2009-09-25
RS20060196A (sr) 2008-08-07
NO20061344L (no) 2006-03-24
EA010261B1 (ru) 2008-06-30
AU2004276015A1 (en) 2005-04-07
US20090036482A1 (en) 2009-02-05
EA200600608A1 (ru) 2006-10-27
US20070043073A1 (en) 2007-02-22
ES2309567T3 (es) 2008-12-16
IL173895A0 (en) 2006-07-05
JP2007507467A (ja) 2007-03-29
EP1675854B1 (en) 2008-06-25
BRPI0414972A (pt) 2006-11-07
MXPA06003349A (es) 2006-06-08
KR20060092220A (ko) 2006-08-22
HK1096548A1 (zh) 2007-06-01
CA2540083A1 (en) 2005-04-07
ATE399169T1 (de) 2008-07-15
DE602004014630D1 (de) 2008-08-07
WO2005030771A1 (en) 2005-04-07
EP1675854A1 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
US12264132B2 (en) 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
JP6986032B2 (ja) Ｊａｋ阻害剤としてのピロロピリミジン化合物の結晶
CN109134448B (zh) 杂环化合物及其盐、制备方法、用途和药物
KR20060072142A (ko) Ｃｒｆ 길항제 및 이환식 복소환 화합물
TW201625556A (zh) Ｉｒａｋ抑制劑及彼等之用途
CN103097361A (zh) 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮作为parp抑制剂及其应用
CN102458580A (zh) 作为mek抑制剂的杂环化合物
CN118103371A (zh) 一种egfr抑制剂及其制备方法和用途
CN101948430A (zh) 青藤碱衍生物及其制备方法和应用
CN100415745C (zh) 作为可诱导的no合成酶抑制剂的咪唑并吡啶衍生物
JP2023110094A (ja) Ｔｃｒ－ｎｃｋ相互作用の阻害剤としてのクロメン誘導体
AU2021320763A1 (en) Compositions for modulating splicing
CN115135646A (zh) 取代的多环化合物及其药物组合物和用途
WO2022028353A1 (zh) 作为bcl-2抑制剂的杂环化合物
CN106565657A (zh) 一种具抗肿瘤活性的橙皮素肉桂酸酯类化合物及其合成方法
CN106083817B (zh) 吡非尼酮衍生物及其制备方法
TWI325322B (en) Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a] pyrimidin-4-one; and 7-pyrimidiny-2,3-dihydroimidazo[1,2-a] pyrimidin-5(1h)one derivatives
CN113549046B (zh) 一种双联苄地钱素s衍生物及其制备方法和应用
CN110028439B (zh) 邻苯二甲酰亚胺类衍生物及其制备方法和用途
CN117917243A (zh) 化合物用于治疗水痘-带状疱疹病毒引起的疾病的用途
CN105878243B (zh) 吡非尼酮衍生物在制药中的应用
CN117917240A (zh) 化合物用于治疗单纯疱疹病毒感染及其相关疾病或病症的用途
CN118702697A (zh) 苯甲酰基吡咯并嘧啶类衍生物及其用途和制备方法
CN118666846A (zh) 苯甲羰基吲哚类衍生物及其用途
CN117917239A (zh) 化合物用于治疗副流感病毒引起的疾病的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096548

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1096548

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080903

Termination date: 20110930